Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1Phase 2 1

Status

Recruiting 4Completed 4Withdrawn 2Terminated 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Cisplatin 270Oxaliplatin 195Carboplatin 191Capecitabine 184Docetaxel 178apatinib 164Paclitaxel 163Bevacizumab 159Gemcitabine 156Radiotherapy 147camrelizumab 146Fluorouracil 144Cyclophosphamide 126Irinotecan 120Drug Therapy 119sintilimab 108Etoposide 99anlotinib 90S 1 (combination) 89Leucovorin 86pembrolizumab 85toripalimab 78Pemetrexed 78Doxorubicin 77tislelizumab 76Dexamethasone 71Trastuzumab 65Neoadjuvant Therapy 65Rituximab 62Cetuximab 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Antibodies, Monoclonal × Clear all
NCT05073250 2023-05-12

IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.

Chinese PLA General Hospital

Phase 2 Unknown
40 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡